泛-RAF抑制剂(CCT196969) | 1163719-56-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 泛-RAF抑制剂(CCT196969)
• 中文别名: 化合物CCT196969
• 英文名称: CCT196969
• 英文别名: 1-(3-(tert-butyl)-1-phenyl-1H-pyrazol-5-yl)-3-(2-fluoro-4-((3-oxo-3,4-dihydropyrido[2,3-b]pyrazin-8-yl)oxy)phenyl)urea；1-(5-tert-butyl-2-phenylpyrazol-3-yl)-3-[2-fluoro-4-[(3-oxo-4H-pyrido[2,3-b]pyrazin-8-yl)oxy]phenyl]urea
• CAS: 1163719-56-9
• 化学式: C₂₇H₂₄FN₇O₃
• 分子量: 513.531
• InChiKey: KYYKGSDLXXKQCR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  38
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  123
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  8-(4-amino-3-fluorophenoxy)pyrido[2,3-b]pyrazin-3(4H)-one 、 3-(tert-butyl)-5-isocyanato-1-phenyl-1H-pyrazole 生成 泛-RAF抑制剂(CCT196969)
  参考文献：
  名称：

  PYRIDO[2,3-B]PYRAZIN-8-SUBSTITUTED COMPOUNDS AND THEIR USE

  摘要：

  本发明涉及治疗增生性疾病、癌症等的治疗化合物领域，更具体地涉及一些如下所述的吡啶并[2,3-b]吡嗪-8-取代化合物，它们可以抑制RAF（例如B-RAF）活性。本发明还涉及包含这些化合物的制药组合物，以及在体内外使用这些化合物和组合物来抑制RAF（例如BRAF）活性、抑制受体酪氨酸激酶（RTK）活性、抑制细胞增殖以及治疗通过抑制RAF、RTK等获得改善的疾病和疾病。这些增生性疾病包括癌症（例如结肠癌、黑色素瘤）等。

  公开号：

  US20160002230A1

文献信息

• [EN] PYRIDO[2,3-B]PYRAZINE-8-SUBSTITUTED COMPOUNDS AND THEIR USE<br/>[FR] COMPOSÉS PYRIDO[2,3-B]PYRAZINE SUBSTITUÉS EN POSITION 8 ET LEUR UTILISATION
  申请人：CANCER REC TECH LTD

  公开号：WO2009077766A1

  公开（公告）日：2009-06-25

  The present invention pertains generally to the field of therapeutic compounds for treating proliferative disorders, cancer, etc., and more specifically to certain pyrido[2,3-b]pyrazin-8-substituted compounds, as described herein, which, inter alia, inhibit RAF (e.g., B RAF) activity. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit RAF (e.g., BRAF) activity, to inhibit receptor tyrosine kinase (RTK) activity, to inhibit cell proliferation, and in the treatment of diseases and disorders that are ameliorated by the inhibition of RAF, RTK, etc., proliferative disorders such as cancer (e.g., colorectal cancer, melanoma), etc.

  本发明一般涉及用于治疗增殖性疾病、癌症等的治疗化合物领域，更具体地涉及到本文所述的某些吡啶并[2,3-b]吡嗪-8-取代化合物，该化合物在某些情况下抑制RAF（例如BRAF）活性。本发明还涉及包含这些化合物的药物组合物，以及利用这些化合物和组合物在体内外抑制RAF（例如BRAF）活性、抑制受体酪氨酸激酶（RTK）活性、抑制细胞增殖，并用于治疗通过抑制RAF、RTK等而得到改善的疾病和疾患，如癌症（例如结直肠癌、黑色素瘤）等。
• [EN] 1 -(5-TERT-BUTYL-2-ARYL-PYRAZOL-3-YL)-3-[2-FLUORO-4-[(3-OXO-4H-PYRIDO[2, 3-B]PYRAZIN-8-YL)OXY]PHENYL]UREA DERIVATIVES AS RAF INHIBITORS FOR THE TREATMENT OF CANCER<br/>[FR] DÉRIVÉS DE 1-(5-TERT-BUTYL-2-ARYL-PYRAZOL-3-YL)-3-[2-FLUORO-4-[(3-OXO-4H-PYRIDO[2, 3-B]PYRAZIN-8-YL)OXY]PHÉNYL]URÉE EN TANT QU'INHIBITEURS DE RAF POUR LE TRAITEMENT D'UN CANCER
  申请人：CANCER REC TECH LTD

  公开号：WO2015075483A1

  公开（公告）日：2015-05-28

  The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain 1-(5-tert-butyl-2-aryl-pyrazol-3-yl)- 3-[2-fluoro-4-[(3-oxo-4H-pyrido[2,3-b]pyrazin-8-yl)oxy]phenyl]urea compounds (referred herein as "TBAP compounds") that, inter alia, inhibit RAF (e.g., BRAF, CRAF, etc.). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit RAF (e.g., BRAF, CRAF, etc.); and to treat disorders including: proliferative disorders; cancer (including, e.g., malignant melanoma, colorectal carcinoma, pancreatic adenocarcinoma); inflammation; immunological disorders; viral infections; fibrotic disorders; disorders associated with a mutated form of RAF (e.g., BRAF, CRAF, etc.); disorders ameliorated by the inhibition of RAF (e.g., BRAF, CRAF, etc.); disorders ameliorated by the inhibition of mutant BRAF; disorders ameliorated by the inhibition of BRAF and CRAF; disorders associated with RAS mutations and/or MAPK pathway activation; disorders ameliorated by the inhibition of SRC, p38, FGFRA, VEGFR-2 (KDR), and/or LCK; etc.

  本发明一般涉及治疗化合物领域。更具体地，本发明涉及某些1-(5-叔丁基-2-芳基吡唑-3-基)-3-[2-氟-4-[(3-氧代-4H-吡啶[2,3-b]吡嗪-8-基)氧基]苯基]脲类化合物（以下简称“TBAP化合物”），其中包括抑制RAF（例如BRAF，CRAF等）的化合物。本发明还涉及包含这样的化合物的制药组合物，以及使用这样的化合物和组合物在体内外抑制RAF（例如BRAF，CRAF等）和治疗包括增生性疾病、癌症（包括恶性黑色素瘤、结肠直肠癌、胰腺腺癌）、炎症、免疫性疾病、病毒感染、纤维化疾病、与RAF突变形式相关的疾病（例如BRAF，CRAF等）、通过抑制RAF改善的疾病（例如BRAF，CRAF等）、通过抑制突变BRAF改善的疾病、通过抑制BRAF和CRAF改善的疾病、与RAS突变和/或MAPK途径激活相关的疾病、通过抑制SRC、p38、FGFRA、VEGFR-2（KDR）和/或LCK改善的疾病等。
• Pyrido[2,3-b]pyrazin-8-substituted compounds and their use
  申请人：Institute of Cancer Research: Royal Cancer Hospital (The)

  公开号：US08198279B2

  公开（公告）日：2012-06-12

  The present invention pertains generally to the field of therapeutic compounds for treating proliferative disorders, cancer, etc., and more specifically to certain pyrido[2,3-b]pyrazin-8-substituted compounds, as described herein, which, inter alia, inhibit RAF (e.g., B—RAF) activity. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit RAF (e.g., BRAF) activity, to inhibit receptor tyrosine kinase (RTK) activity, to inhibit cell proliferation, and in the treatment of diseases and disorders that are ameliorated by the inhibition of RAF, RTK, etc., proliferative disorders such as cancer (e.g., colorectal cancer, melanoma), etc.

  本发明一般涉及治疗增生性疾病、癌症等治疗化合物领域，更具体地涉及某些在此处描述的吡啶并[2,3-b]吡嗪-8-取代化合物，其抑制 RAF (例如 B-RAF) 活性等。本发明还涉及包含这种化合物的制药组合物，以及在体内外使用这种化合物和组合物来抑制 RAF (例如 BRAF) 活性、抑制受体酪氨酸激酶 (RTK) 活性、抑制细胞增殖，以及治疗通过抑制 RAF、RTK等而改善的疾病和紊乱，如增生性疾病（例如结肠直肠癌、黑色素瘤）等。
• Pyrido[2,3-b]pyrazin-8-substituted Compounds and Their Use
  申请人：Springer Caroline Joy

  公开号：US20120238568A1

  公开（公告）日：2012-09-20

  The present invention pertains generally to the field of therapeutic compounds for treating proliferative disorders, cancer, etc., and more specifically to certain pyrido[2,3-b]pyrazin-8-substituted compounds, as described herein, which, inter alia, inhibit RAF (e.g., B-RAF) activity. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit RAF (e.g., BRAF) activity, to inhibit receptor tyrosine kinase (RTK) activity, to inhibit cell proliferation, and in the treatment of diseases and disorders that are ameliorated by the inhibition of RAF, RTK, etc., proliferative disorders such as cancer (e.g., colorectal cancer, melanoma), etc.

  本发明涉及治疗增生性疾病、癌症等的治疗化合物领域，更具体地涉及某些在此处描述的吡啶并[2,3-b]吡嗪-8-取代化合物，它们在诸多方面抑制RAF（例如B-RAF）活性。本发明还涉及包含这些化合物的药物组合物，以及在体外和体内使用这些化合物和组合物来抑制RAF（例如BRAF）活性，抑制受体酪氨酸激酶（RTK）活性，抑制细胞增殖，并用于治疗由于抑制RAF、RTK等而改善的疾病和疾病，如增生性疾病（例如结直肠癌、黑色素瘤）等。
• Pyrido[2,3-B]pyrazin-8-substituted compounds and their use
  申请人：Cancer Research Technology Limited

  公开号：US08912191B2

  公开（公告）日：2014-12-16

  The present invention pertains generally to the field of therapeutic compounds for treating proliferative disorders, cancer, etc., and more specifically to certain pyrido[2,3-b]pyrazin-8-substituted compounds, as described herein, which, inter alia, inhibit RAF (e.g., B-RAF) activity. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit RAF (e.g., BRAF) activity, to inhibit receptor tyrosine kinase (RTK) activity, to inhibit cell proliferation, and in the treatment of diseases and disorders that are ameliorated by the inhibition of RAF, RTK, etc., proliferative disorders such as cancer (e.g., colorectal cancer, melanoma), etc.

  本发明涉及治疗增殖性疾病、癌症等治疗化合物领域，更具体地说，涉及某些在此处描述的吡啶并[2,3-b]吡嗪-8-取代化合物，其在其中包括抑制RAF（例如B-RAF）活性。本发明还涉及包含这种化合物的药物组合物，以及使用这种化合物和组合物，无论是体内还是体外，来抑制RAF（例如BRAF）活性，抑制受体酪氨酸激酶（RTK）活性，抑制细胞增殖，并用于治疗由于抑制RAF、RTK等而改善的疾病和疾病，如增殖性疾病（例如结直肠癌、黑色素瘤）等。